Abbott Will Study Prostate Cancer Drug Atrasentan For Early-Stage/Prevention
Executive Summary
Abbott plans to file an NDA for its prostate cancer therapy atrasentan in late 2003, the company told securities analysts at its June 21 R&D Day in New York City.